These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 921240)

  • 1. Effect of cefamandole nafate on the toxicity of tobramycin.
    Wold JS; Turnipseed SA; Broddle WD; Owen NV
    Antimicrob Agents Chemother; 1977 Oct; 12(4):465-9. PubMed ID: 921240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicologic evaluation of cefamandole nafate in laboratory animals.
    Wold JS; Welles JS; Owen NV; Gibson WR; Morton DM
    J Infect Dis; 1978 May; 137 Suppl():S51-S59. PubMed ID: 650004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicology of vancomycin in laboratory animals.
    Wold JS; Turnipseed SA
    Rev Infect Dis; 1981; 3 suppl():S224-9. PubMed ID: 7342285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability and pain study of cefamandole nafate.
    Foster TS; Shrewsbury RP; Coonrod JD
    J Clin Pharmacol; 1980; 20(8-9):526-33. PubMed ID: 7000857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin.
    Jones RN; Fuchs PC; Sommers HM; Gavan TL; Barry AL; Gerlach EH
    Antimicrob Agents Chemother; 1980 Apr; 17(4):750-6. PubMed ID: 6446880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delineation of the relative antibacterial activity of cefamandole and cefamandole nafate.
    Turner JR; Preston DA; Wold JS
    Antimicrob Agents Chemother; 1977 Jul; 12(1):67-72. PubMed ID: 18988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydrolysis of cefamandole nafate to cefamandole in vivo.
    Wold JS; Joost RR; Black HR; Griffith RS
    J Infect Dis; 1978 May; 137 Suppl():S17-S24. PubMed ID: 650001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of cefamandole plus either gentamicin or tobramycin in therapy of severe gram-negative bacterial infections.
    Gentry LO
    J Infect Dis; 1978 May; 137 Suppl():S144-S149. PubMed ID: 349093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cefamandole: in vitro and in vivo activity].
    Martinetto P; Valtz A; Cavallo GP; Angeretti A
    G Batteriol Virol Immunol; 1979; 72(1-6):44-61. PubMed ID: 553842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro comparison of synergism between cefamandole and gentamicin or tobramycin by the triple layer agar method with enzymatic inactivation.
    Yourassowsky E; Schoutens E; Van der Linden MP; Lismont MJ
    Infection; 1979; 7(5):237-9. PubMed ID: 389805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of cefamandole, cefoxitin, cefuroxime, and carbenicillin, alone and in combination with aminoglycosides against Serratia marcescens.
    Miller MA; Yousuf M; Griffin PS; Bartlett M; Crane JK
    Microbiol Immunol; 1979; 23(10):955-64. PubMed ID: 390321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formylation of glucose by cefamandole nafate at alkaline pH.
    Indelicato JM; Stewart BA; Engel GL
    J Pharm Sci; 1980 Oct; 69(10):1183-8. PubMed ID: 7420288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of cefamandole nafate to cefamandole by microbiological assay.
    Winely CL; Spears JC; Scott JK
    Antimicrob Agents Chemother; 1979 Sep; 16(3):424-6. PubMed ID: 41479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicentre study of the susceptibility of a variety of bacteria to cephalothin, cefamandole, tobramycin and gentamicin.
    du T Naudé W; van den Ende J; Botha P; Forder A; Hyland J; de Klerk HC; Neiteler BF; Koornhof HJ; Robinson R; Robins-Browne R; Block C; Appelbaum PC; Africa CW; van Rensburg AJ; Jooste PJ; Crewe-Browne H; Fernandez A
    S Afr Med J; 1977 Nov; 52(20):798-800. PubMed ID: 305120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of cefamandole nafate on blood coagulation and platelet function.
    Custer GM; Briggs BR; Smith RE
    Antimicrob Agents Chemother; 1979 Dec; 16(6):869-72. PubMed ID: 533268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydrolysis of cefamandole nafate in dialysis patients.
    Nielsen RL; Wolen R; Luft FC; Ozawa T
    Antimicrob Agents Chemother; 1979 Nov; 16(5):683-5. PubMed ID: 526012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the nephrotoxicity of aminoglycoside antibiotics and protection from these effects (3). Protective effect of latamoxef against tobramycin nephrotoxicity and its protective mechanism.
    Kojima R; Ito M; Suzuki Y
    Jpn J Pharmacol; 1986 Nov; 42(3):397-404. PubMed ID: 3820859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empiric therapy for infections in patients with granulocytopenia. Continuous v interrupted infusion of tobramycin plus cefamandole.
    Feld R; Rachlis A; Tuffnell PG; Duncan I; Moran L; Pinfold P; DeBoer G
    Arch Intern Med; 1984 May; 144(5):1005-10. PubMed ID: 6712393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The in vitro activity of cefamandole against 3312 bacterial isolates. A Norwegian multicentre study.
    Digranes A; Bjorvatn B
    NIPH Ann; 1980 Dec; 3(2):141-7. PubMed ID: 7219840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The nephrotoxicity and renal accumulation of amikacin, tobramycin and gentamycin in rats, rabbits and guinea pigs.
    Sairio E; Kasanen A; Kangas L; Nieminen AL; Nieminen L
    Exp Pathol (Jena); 1978; 15(6):370-5. PubMed ID: 744211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.